Interim results from a world-first trial led by UCL researchers have found an existing drug, alpha-lipoic acid, shows early ...
The International Progressive MS Alliance announces the launch of its MS Clinical and Imaging Data Resource (CIDR), which provides the academic and research community access to anonymized and ...
The International Progressive MS Alliance announces the launch of its MS Clinical and Imaging Data Resource (CIDR), which provides the academic and research community access to anonymized and ...
Australia's only dedicated stem cell resource for multiple sclerosis (MS) research has expanded significantly this year, ...
New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine suggests that a therapy called Tolebrutinib could reduce disability progression in ...
The International Progressive MS Alliance announces the MS Clinical and Imaging Data Resource (MS CIDR) is now accepting applications for data access. Available exclusively to the MS research ...
A potential treatment for progressive multiple sclerosis (MS) will continue in a world-first multi-arm, multi-stage adaptive trial after showing ...
Progressive multiple sclerosis encompasses both primary and secondary forms characterised by a sustained increase in neurological disability independent of acute relapses. Pathologically, it reflects ...
NASHVILLE, Tennessee — For the first time, the majority of patients with multiple sclerosis (MS) in the United States are, or soon will be, over age 55, a phenomenon that's driving a shift in ...
Hosted on MSN
Dealing with brain fog when you have progressive MS
Multiple sclerosis (MS) is best known for the physical symptoms it can cause, such as numbness, weakness, spasticity, and difficulty walking. But this autoimmune disease of the central nervous system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results